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Objective: Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a 
real-life, Brazilian multicenter study. Subjects and methods: Characteristics of acromegaly patients 
treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with 
at least two IGF-I measurements on PEGV were included. Efficacy was defined as any normal IGF-I 
measurement during treatment. Safety data were reviewed. Predictors of response were determined 
by comparing controlled versus uncontrolled patients. Results: 109 patients [61 women; median age at 
diagnosis 34 years; 95.3% macroadenomas] from 10 Brazilian centers were studied. Previous treatment 
included surgery (89%), radiotherapy (34%), somatostatin receptor ligands (99%), and cabergoline 
(67%). Before PEGV, median levels of GH, IGF-I and IGF-I % of upper limit of normal were 4.3 µg/L, 
613 ng/mL, and 209%, respectively. Pre-diabetes/diabetes was present in 48.6% and tumor remnant in 
71% of patients. Initial dose was 10 mg/day in all except 4 cases, maximum dose was 30 mg/day, and 
median exposure time was 30.5 months. PEGV was used as monotherapy in 11% of cases. Normal 
IGF-I levels was obtained in 74.1% of patients. Glycemic control improved in 56.6% of patients with 
pre-diabetes/diabetes. Exposure time, pre-treatment GH and IGF-I levels were predictors of response. 
Tumor enlargement occurred in 6.5% and elevation of liver enzymes in 9.2%. PEGV was discontinued in 
6 patients and 3 deaths unrelated to the drug were reported. Conclusions: In a real-life scenario, PEGV 
is a highly effective and safe treatment for acromegaly patients not controlled with other therapies. 
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INTRODUCTION
At target cells, two distinct receptor-binding sites of 
the GH molecule bind to the extracellular domains of 
two identical pre-dimerized growth hormone receptors 
(GHR) forming an active 2:1 complex. Activation 
of GHR triggers a cascade of intracellular signaling 
including the JAK-STAT pathway, which is a key mediator 
of many genomic actions of GH (1,2). Pegvisomant 
(PEGV) is a genetically engineered analog of human 
GH with a single-amino-acid substitution at position 
120 (glycine) of binding site 2 of the GH molecule that 
promotes GHR antagonism. Its molecular structure also 
comprises amino acid substitutions within GH binding 
site 1 and addition of polyethylene glycol moieties that 
increase the half-life and reduce the immunogenicity 
of the compound. When PEGV binds to the GHR, it 
inhibits IGF-I synthesis and release (3,4).
The development of PEGV has opened a new 
perspective in acromegaly treatment (3,4). Despite 
that many patients obtain biochemical control of the 
disease with surgery, radiotherapy and/or medical 
therapy with somatostatin receptor ligands (SRL) and/
or cabergoline, a significant proportion of acromegaly 
patients remain inadequately controlled and in need 
of additional treatment (5). Accordingly, PEGV was 
approved in Europe, USA and other countries around 
the world for the treatment of acromegaly in patients 
previously treated by surgery or radiotherapy and not 
controlled with maximum doses of SRLs (4,6). In 
these cases, PEGV may be used as monotherapy or in 
combination therapy with SRL and/or cabergoline. 
In Brazil, PEGV was approved to be commercialized 
in 2005, but its therapeutic use is not included in 
the 2013 and 2018 reports on the Clinical Protocol 
and Therapeutic Guidelines for Acromegaly of the 
Ministry of Health, due to cost-effectiveness issues 
(7,8). As a consequence, PEGV treatment in Brazil is 
not reimbursed and its use is limited and only possible 
through “judicialization” – legal cases brought by 
individuals claiming their constitutional rights using 
the judicial system, or exceptionally, by individual out-
of-pocket expenditures (9).  
Sustained PEGV concentrations are crucial to its 
efficacy, since the drug is a reversible, competitive GHR 
antagonist (3). In the pivotal long-term clinical trials 
with PEGV, normalization of serum IGF-I was observed 
in up to 97% of patients treated with PEGV during 
12 months with doses as high as 40 mg/day (10,11). 
However, efficacy has been lower in observational real-
life studies, where high doses are rarely used, as the 
recommended dose range by the regulatory agencies 
is 10-30 mg daily (4). A recent report from the 
ACROSTUDY, an observational registry intended to 
collect data on PEGV therapy, including 2,090 patients 
treated with PEGV up to 12 years in 15 countries, found 
that the percentage of patients with normal IGF-I levels 
increased from 53% at year 1 to 73% at year 10, and 
not surprisingly, accompanied by an average daily dose 
increment from 12.8 mg at year 1 to 18.9 mg at year 10 
(12). In the same report, serious adverse events related 
to the drug, as evaluated by the treating physicians, 
were described in 2.3% of the patients. Elevation of 
liver enzymes (ALT or AST) greater than three times 
in relation to pre-treatment levels was observed in 3% 
of the cases. Most patients (72.2%) had no change in 
tumor size relative to the previous scan, 16.8% had a 
decrease, 6.8% an increase and 4.3% had both (12).   
The present real-life study was designed to obtain 
information on the Brazilian experience with PEGV 
treatment in acromegaly patients. We have collected 
clinical, laboratorial and radiological data from 10 
reference centers specialized in the management of 
pituitary diseases from different regions of Brazil. 
The primary aim was to examine efficacy and safety of 
PEGV treatment, followed by identification of good 
predictors of therapeutic response.    
SUBJECTS AND METHODS
This is a retrospective, multicenter, real-life study, 
involving acromegaly patients treated with PEGV in 
10 pituitary reference centers in Brazil. Diagnosis of 
acromegaly was made according to clinical features and 
elevated and/or non-glucose-suppressible serum GH 
levels, associated with increased IGF-I levels adjusted 
for age (13). A GH-secreting pituitary adenoma was 
evidenced by imaging at diagnosis in all cases, and the 
tumors were classified as micro (<1 cm) or macroadenoma 
(≥1 cm) according to the largest diameter. 
Clinical, laboratorial and radiological characteristics 
of the study group were reviewed at diagnosis (DIAGN), 
just before PEGV treatment (PEGV-OFF) and during 
PEGV treatment until the last visit available (PEGV-ON). 
Information was obtained regarding age, gender, GH 
and IGF-I levels, tumor size, previous and concomitant 
treatments, glucose homeostasis, initial and maximal 
PEGV dose, and duration of treatment. All patients 



















Brazilian pegvisomant study in acromegaly
Arch Endocrinol Metab. 2019;63/4
treatment were included. Since this was a real-life study, 
serum IGF-I levels were determined at local laboratories 
and the results were interpreted according to the age-
adjusted reference range for each specific assay used at 
the different settings. To standardize the results, serum 
IGF-I levels were expressed as a percentage of the upper 
limit of the normal (%ULN) reference range of each 
method. Indication and monitoring of PEGV treatment 
were carried out according to the treating physician’s 
clinical judgment, but data on liver enzymes, glucose and 
glycated hemoglobin A1c (HbA1c) levels, and tumor 
growth during medical treatment were determined in 
a routine practice in all cases. The main indication to 
initiate PEGV was uncontrolled disease after surgery and 
maximum dose of first generation SRLs and cabergoline, 
with or without previous radiotherapy. In few cases, 
PEGV was initiated in patients participating in clinical 
trials or due to adverse events of other medications. 
Efficacy was defined as any IGF-I measurement within 
the normal reference range adjusted for age during 
PEGV treatment. Safety data, including adverse events 
and dropouts, were also reviewed. Predictors of response 
were evaluated by comparing results from controlled 
and uncontrolled patients. 
Statistical analysis
For the descriptive analysis, categorical variables were 
expressed as the percentage and frequency, and the 
numerical variables were expressed as the median 
(minimum – maximum values) or mean ± SD, 
according to the distribution of the sample. The Mann-
Whitney U test was used to evaluate the differences 
between hormonal levels at diagnosis, before and after 
PEGV therapy, as well as in the comparison between 
controlled and uncontrolled groups of patients. Fisher’s 
exact test was used to examine the association between 
categorical variables. The Spearman test was used for 
correlations. The difference was considered statistically 
significant when p <0.05.
RESULTS
Study population
A total of 109 patients (61 women and 48 men) 
were included in the study (Table 1). At diagnosis, 
the median age was 34 years (range 12-82) and a 
GH-secreting macroadenoma was demonstrated in 
103 (95.4%) patients and a microadenoma in only 5 
patients (4.7%). In one case the information about 
tumor size was unavailable. Median GH levels were 
24.2 mg/L (0.9 – 1136 mg/L), median IGF-I levels 
were 1053 ng/mL (396 – 2376 mg/L) and median 
IGF-I ULN were 327% (120 – 756%). The results 
of 27 patients from one single center have been 
previously published (14). 
Table 1. Clinical, laboratorial and radiological characteristics of the study population at diagnosis and just before pegvisomant treatment (PEGV-OFF)
Total (N = 109) Women (N = 61) Men (N = 48)
At diagnosis
Age (yrs) 34 (12 – 82) 37 (12 – 82) 34 (12 – 63)
Micro/Macroadenoma (n) 5/103 2/58 3/45
GH (µg/L) 24.2 (0.9 – 1136) 20.8 (3.0 – 680) 26.0 (0.9 – 1136)
IGF-I (ng/mL) 1053 (396 – 2376) 910 (396 – 2376) 1190 (409 – 2320)
IGF-I (%ULN) 327 (120 – 756) 313 (129 – 672) 349 (120 – 756) 
At PEGV-OFF
Previous surgery (%) 97 (89) 53 (87) 44 (92)
Previous radiotherapy (%) 37 (34) 21 (34) 16 (33)
Previous SRL (%) 108 (99) 60 (98) 48 (100)
Previous cabergoline (%) 73 (67) 39 (64) 34 (71)
Pre-diabetes/Diabetes (%) 53 (49) 33 (54) 20 (42)
Tumour remnant (%) 77 (71) 39 (64) 38 (79)
GH (µg/L) 4.3 (0.71 – 209) 4.0 (0.72 – 209) 4.7 (0.71 – 101)
IGF-I (ng/mL) 613 (262 – 1503) 569 (275 – 1503) 650 (262 – 1312)
IGF-I (%ULN) 209 (99 – 637) 194 (99 – 637) 220 (100 – 596) 
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A total of 97 (89%) patients were submitted to 
transsphenoidal surgery, 37 (34%) patients were treated 
with radiotherapy and 73 (67%) received cabergoline. 
All but one patient were medically treated with SRL 
prior to PEGV. Just before PEGV treatment (PEGV-
OFF), the median GH levels were 4.3 mg/L (0.71 – 
209 mg/L), median IGF-I levels were 613 ng/mL (262 
– 1503 ng/mL) and median IGF-I ULN were 209% 
(99.7 – 637%). The only patient with an IGF-I ULN 
below 100% was a 15-year-old girl with an IGF-I level 
of 843 ng/mL (ULN = 850 ng/mL) and GH level 
of 2.2 mg/L after surgery, octreotide and cabergoline, 
who was still growing and complaining of severe joint 
pain. Pre-diabetes/diabetes were present in 53 (48.6%) 
of the patients, and 77 (71%) had a tumor remnant 
in the magnetic resonance imaging (MRI) (Table 1). 
There were no significant differences between men and 
women at diagnosis and at PEGV-OFF.  
Pegvisomant treatment (PEGV-ON)
The initial dose of PEGV was 10 mg/day in 105 
patients. In the other 4 cases, initial dose was 15 
mg, 20 mg and in two cases 40 mg/week in two 
applications (5.7 mg/day). In 12 (11%) of the cases, 
PEGV was used as monotherapy in the whole period 
of observation, while it was associated with SRL in 92 
and/or with cabergoline in 23 patients, at different 
periods of time throughout the treatment, following 
treating physician’s judgement. The median duration 
of PEGV exposure was 30.5 months (2 – 124 
months), with a median maximum dose of 10 mg/
day. The initial dose was maintained during the entire 
period of PEGV exposure in 58 (53%) patients, it was 
increased to 15 mg/day in 12 (11%), to 20 mg/day in 
26 (24%) and to 30 mg/day in only 11 (10.2%). None 
of the patients received daily dose of PEGV higher 
than 30 mg/day (Table 2). No statistically significant 
differences between men and women were noted at 
PEGV-ON.  
Normalization of serum IGF-I levels at any point 
during therapy was obtained in 80 (74.1%) patients: 
11 (92%) in monotherapy and 69 (71%) in combined 
treatment. The median maximum dose of PEGV 
in monotherapy was 15 mg/day and in combined 
treatment was 10 mg/day, but these values were not 
statistically different. Figure 1 shows individual IGF-I 
ULN values before and after PEGV treatment in the 
whole cohort. In the PEGV-ON period of the study, 
median IGF-I levels and IGF-I ULN were 206 ng/mL 
(30 – 946) and 84.4% (12.6 – 253.3), respectively, 
values significantly lower in relation to PEGV-OFF 
values (p < 0.00001; Figure 2). There was no difference 
in the PEGV treatment outcomes comparing patients 
who were previously irradiated with those who were 
not. Normal IGF-I was observed in 26 of 37 patients 
(70.3%) previously treated with radiotherapy and in 
54 of 72 patients (75%) not irradiated. Improvement 
of glycemic control determined by fasting glucose 
and HbA1c levels was documented in 30 of 53 
patients (56.6%) with pre-diabetes/diabetes at PEGV-
OFF period. 
Table 2. Therapeutic approach and efficacy of pegvisomant (PEGV) treatment in Brazilian acromegaly patients
Total (N = 109) Women (N = 61) Men (N = 48)
PEGV initial dose 10 mg/day (%) 105 (96) 58 (95) 47 (98)





















PEGV monotherapy (%) 12 (11) 8 (13.1) 4 (8.3)
PEGV + SRL (%) 92 (84.4) 53 (87) 39 (81.2)
PEGV + cabergoline (%) 23 (21) 11 (18) 12 (25)
PEGV exposure (months) 30.5 (2 – 124) 30.0 (2 – 110) 30.5 (2 – 124)
IGF-I (ng/mL) 206 (30 – 946) 192 (30 – 828) 220 (88 – 946)
IGF-I (%ULN) 84.4 (12.6 – 253.3) 72.5 (12.6 – 253.3) 89.5 (21.6 – 246)
Normal IGF-I on PEGV (%) 80 (74.1) 44 (73.3) 36 (75.0)
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Tumor enlargement was described in 5 (6.5%) of 77 
patients with tumor remnant at PEGV-OFF. Only one 
of the 5 patients was in monotherapy, and in all cases 
it was observed in aggressive tumors and considered 
unrelated to PEGV treatment by the treating physician. 
Elevation of liver enzymes greater than 3 times in relation 
to pre-treatment levels occurred in 10 (9.2%) patients, 
lipohypertrophy, pain at injection site and headache 
were reported by 5, 3 and 2 patients, respectively 
(Table 3). Six women and no man discontinued PEGV 
treatment, and the causes were lipohypertrophy, pain 
at injection site, headache, elevation of liver enzymes, 
700
600
IGF-I BEFORE PEGV (ULN%)













Figure 1. Individual IGF-I levels, expressed as a percentage of the age-adjusted upper limit of normal (ULN) range, before (dark blue circles) and after 
(light blue circles) pegvisomant (PEGV) treatment in 109 Brazilian patients with acromegaly. 
Figure 2. IGF-I levels at diagnosis, just before pegvisomant treatment (PEGV-OFF) and nadir values after pegvisomant treatment (PEGV-ON) in 109 














At diagnosis PEGV-OFF PEGV-ON
*
p < 0.00001 vs PEG-OFF
Table 3. Safety data on pegvisomant treatment in Brazilian acromegaly patients
Total (N = 109) Women (N = 61) Men (N = 48)
Tumour enlargement (%)* 5 (6.5) 5 (12.8)   0 (0)
Elevation of liver enzymes (%) 10 (9.2) 5 (8.2) 5 (10.4)
Lipohypertrophy (%) 5 (4.6) 4 (6.5) 1 (2.1)
Pain at injection site (%) 3 (2.7) 3 (4.9) 0 (0)
Headache (%) 2 (1.8) 2 (3.3) 0 (0)
Treatment discontinuation (%)# 6 (5.5) 6 (9.8) 0 (0)
Death (unrelated to therapy) (%)§ 3 (2.7) 2 (3.3) 1 (2.1)
* In 77 patients with tumor remnant at beginning of treatment (39 women, 38 men).
# Lipohypertrophy, pain at injection site, headache, elevation of liver enzymes, allergic reaction, pregnancy.
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allergic reaction, and pregnancy. Three deaths were 
observed, all considered not related to PEGV therapy: 
a sudden death of unknown cause, one due to stroke 
and one caused by severe heart failure. 
Predictors of treatment response
Table 4 shows the comparison of clinical and 
laboratorial characteristics at diagnosis and PEGV-OFF 
phases between patients controlled and uncontrolled at 
PEGV-ON. The median duration of PEG exposure was 
41 (2 – 120) months in the controlled group, which 
was significantly higher than 22 (3 – 124) months 
observed in the uncontrolled group (p = 0.03). At 
PEG-OFF, median GH levels were significantly lower 
in the controlled patients [3.75 mg/L (0.71 – 101) vs 
7.8 mg/L (1.03 – 209), p < 0.01)], as well as median 
IGF-I levels [570 ng/mL (262 – 1155) vs 717 ng/mL 
(279 – 1503), p < 0.001)] and IGF-I ULN [194% (99 
– 434) vs 241% (124 – 637), p < 0.001)]. There was 
no difference between the two groups regarding age 
at diagnosis, gender, previous radiotherapy, and the 
presence of tumor remnant or pre-diabetes/diabetes.
DISCUSSION
This first Brazilian multicenter real-life study has 
confirmed the conclusion of previous clinical trials and 
observational studies that PEGV is an effective and 
safe medical therapy to acromegaly patients. In fact, 
PEGV might be the only therapeutic option to obtain 
biochemical control in a subgroup of patients who 
remain with active disease after surgery, radiotherapy, 
SRLs and cabergoline (15). Although the analysis of 
surveillance data suggests a biochemical control rate in 
approximately 75% of patients treated with PEGV as 
first-line monotherapy, PEGV is preferably a second-
line medical therapy, as it has no effect on the GH-
secreting adenoma (13,15,16). This recommendation 
is in line with the Brazilian experience, as in our cohort 
89% of patients were operated, all but one patient 
was treated with SRL, 67% received cabergoline and 
roughly one-third was treated with radiotherapy before 
PEGV. 
Acromegaly is associated with enhanced mortality 
and a high morbidity when normalization of GH 
and/or IGF-I levels is not achieved (17). There is some 
evidence that total direct treatment costs are higher 
for patients with uncontrolled compared to those with 
controlled disease (18). Thus, one should expect that 
a medication that promotes biochemical control rate in 
two-third of patients, as observed in our study, would 
result in a cost-effective treatment. However, our study 
was not designed to evaluate this outcome and there 
are still many unanswered questions about the benefits 
of controlled versus uncontrolled disease in relation to 
the economic impacts to health systems (8,18). 
The SRLs octreotide and lanreotide are the first-
line medical therapy in most acromegaly patients, with 
biochemical control observed in 20-40% of patients, 
depending on the study design (13,15,19-22). The 
new generation SRL pasireotide is effective in up to 
20% of patients who do not respond to octreotide or 
lanreotide (23,24). Our result of 74.1% of patients 
achieving normal IGF-I confirms that PEGV is one of 
the most effective drugs to obtain biochemical control 
in acromegaly. This percentage is slightly lower than 
that observed in a previous Brazilian single center 
study, in which 85% of 27 patients were successfully 
Table 4. Comparison of clinical, laboratorial and radiological features between controlled (normal IGF-I levels on pegvisomant (PEGV-ON) and uncontrolled 
acromegaly patients 
Controlled (N = 80) Not controlled (N = 29) P-value
Age at diagnosis (yrs) 35 (12 – 75) 31 (12 – 82) 0.09
Female (%) 44 (55) 17 (58.6) 0.73
Tumour Remnant (%) 55 (68.7) 22 (78.6) 0.32
Previous radiotherapy (%) 26 (32.5) 11 (37.9) 0.59
Pre-Diabetes/Diabetes (%) 36 (45) 17 (58.6) 0.20
PEGV exposure (months) 41 (2 – 120) 22 (3 – 124) 0.03
GH PEGV-OFF (µg/L) 3.75 (0.71 – 101) 7.80 (1.03 – 209) 0.01
IGF-I PEGV-OFF (ng/mL) 570 (262 – 1155) 717 (279 – 1503) < 0.001
IGF-I PEGV-OFF (ULN%) 194 (99 – 434) 241 (124 – 637) < 0.001
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treated (14). In both studies the median daily dose 
of PEGV was 10 mg, and no patient received doses 
higher than 30 mg after a median time of exposure 
of 30.5 months. The results from the single center 
and the present multicenter study in Brazil are 
surprisingly better than expected, as in the last report 
from the ACROSTUDY, an average dose of 12.8 
mg was associated with normal IGF-I in 53% of the 
patients at year 1 (12). A percentage of 73% of normal 
IGF-I, similar to that of our study, was described 
in the ACROSTUDY only at year 10 with a higher 
average dose of 18.9 mg (12). Besides the differences 
attributable to variable doses of PEGV in the studies, 
several other factors have been associated with the 
therapeutic responses to PEGV. Age, gender, body 
mass index, previous radiotherapy and the presence 
of diabetes have been suggested as predictive of the 
PEGV dose required for normalization of IGF-I levels 
(25-27). Height and weight were not available in our 
study, while age, gender, previous radiotherapy and 
diabetes were not correlated to PEGV dose and were 
not predictive of response to PEGV. On the other 
hand, we found that pre-treatment GH and IGF-I 
levels and time of exposure were predictors of response. 
In agreement, baseline GH and IGF-I levels have been 
correlated with the PEGV dose required to normalize 
serum IGF-I in patients with active acromegaly (28). 
Another possible factor influencing the results of 
PEGV therapy in acromegaly among different studies 
is the number of patients in monotherapy and in 
combined therapy with SRLs and/or cabergoline. 
PEGV has shown efficacy rates as high as 97% when 
given in combination with an SRL and delivered once 
or twice weekly (29). In addition, effectiveness might 
continue after SRL discontinuation (30). This number 
is higher than that reported on long-term treatment 
with PEGV as monotherapy in the ACROSTUDY, 
where normal IGF-I was observed in 67.5% of patients 
at 5 years of therapy (31). In our study, PEGV was used 
as monotherapy in the whole period of observation in 
only 11% of the patients, while the vast majority of 
patients were also exposed to SRL at variable times 
during follow-up, and a smaller proportion was co-
exposed to cabergoline. These percentages are fairly 
similar to those of the Brazilian single center study (14), 
and might explain the good efficacy results observed 
in both real-life Brazilian studies, even that a large 
proportion of patients were treated with the lowest 
doses of PEGV. Accordingly, it has been previously 
demonstrated that the combined therapy of SRLs 
with PEGV can normalize IGF-I levels in virtually all 
patients and control tumor size in a vast majority of 
patients if an adequate dose of PEGV is used (32). 
In our study, approximately 60% of patients treated 
with PEGV presented an improvement of their pre-
diabetes/diabetes status, which is very relevant in 
comparison to other medications that are neutral or 
might even worsen glycemic control. A recent meta-
analysis of prospective interventional studies have 
shown that PEGV, in monotherapy or combined 
with SRLs, improves glucose metabolism by reducing 
fasting plasma glucose and insulin levels, HbA1c, and 
insulin resistance, independently of disease control 
(33). In agreement with that, a consensus statement on 
acromegaly therapeutic outcomes has recommended 
PEGV as the best medical option for patients with 
impaired glucose tolerance unresponsive to first-
generation of SRLs, due to its beneficial effect on 
insulin sensitivity and glucose tolerance (15). 
The safety profile in our experience was fairly similar 
to what has been described in previous studies (4,6). 
One of the major concerns related to PEGV therapy 
is the potential growth of the somatotroph pituitary 
adenoma due to reduced feedback mechanisms. 
Tumor enlargement was described in 3.2% out of 
936 patients with a minimum of two available MRI 
examinations in a comprehensive review of 1288 
subjects in ACROSTUDY (34). In the most recent 
ACROSTUDY report, 6.8% of 2090 patients had an 
increase in tumor size, very similar to our findings 
(12). In all of our cases, tumor growth was not 
considered as a consequence of PEGV treatment and 
occurred in patients harboring aggressive GH-secreting 
adenomas unresponsive to multimodal therapies. It is 
possible that SRLs withdrawal might contribute to 
tumor growth in some cases, but it was not possible 
to evaluate the influence of SRLs withdrawal in our 
study due to its real-life design. Mild elevation of liver 
enzymes occurs in 9.2% of our cohort, as compared to 
2.5 % described in other studies (4), and it was a reason 
for PEGV discontinuation in one female patient. In the 
other cases, liver enzymes returned to normal upon 
temporary drug discontinuation, dose reduction or 
without intervention. There were other five dropouts, 
all in women, due to lipohypertrophy, pain, headache, 
allergic reaction, and pregnancy. There were also three 
deaths during follow-up that were considered unrelated 
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In summary, PEGV treatment has been proved to 
be highly effective and safe in a large cohort of Brazilian 
patients with active acromegaly and not controlled with 
all other available therapeutic modalities. It might be 
particularly useful in patients with impaired glucose 
tolerance. In our study, lower pre-treatment GH 
and IGF-I levels and longer time of exposure were 
associated with better response to PEGV therapy.
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